Cystic Fibrosis Clinical Trials in Seattle, Washington

8 studies are recruiting for cystic fibrosis in Seattle, Washington right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Streamlined Treatment of Pulmonary Exacerbations in Pediatrics

   The STOP PEDS RCT is a multicenter, parallel, open label randomized controlled trial evaluating the long-term (one year) and short-term safety and efficacy of two antibiotic treatment strategies for the management of outpatient pulmonary exacerbations (PEx) in the pediatric CF population.

   Stage

   Not phased

   Ages

   3 to 18

   Site

   Seattle Children's Hospital, Seattle, Washington

   Locations

   33 in total

   Run by

   University of Washington, the Collaborative Health Studies Coordinating Center

   See if you can join NCT06654752 on ClinicalTrials.gov

2. Study to Evaluate Biological & Clinical Effects of Significantly Corrected CFTR Function in Infants & Young Children

   This is a two-part, multi-center, prospective longitudinal, exploratory study of highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulators and their impact on children with cystic fibrosis (CF).

   Stage

   Not phased

   Ages

   Up to 10

   Site

   Seattle Children's Hospital, Seattle, Washington

   Locations

   35 in total

   Run by

   Sonya Heltshe

   See if you can join NCT04509050 on ClinicalTrials.gov

3. Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study

   The purpose of this study is to look at pulmonary exacerbations in people with cystic fibrosis (CF) that need to be treated with antibiotics given through a tube inserted into a vein (intravenous or IV). A pulmonary exacerbation is a worsening of respiratory symptoms in people with CF that needs me…

   Stage

   Phase 4

   Ages

   6 and older

   Site

   Seattle Children's Hospital, Seattle, Washington

   Locations

   60 in total

   Run by

   Chris Goss

   See if you can join NCT05548283 on ClinicalTrials.gov

4. Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis

   ARCT-032-02 is a Phase 2, open-label, multicenter, multiple-ascending dose study of ARCT-032 in adults with CF who are not eligible for CFTR modulator therapy or are not taking CFTR modulators due to drug intolerance, poor response, or lack of access to modulators.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Seattle Children's Hospital, Seattle, Washington

   Locations

   13 in total

   Run by

   Arcturus Therapeutics, Inc.

   See if you can join NCT06747858 on ClinicalTrials.gov

5. Health Outcomes of Parents With Cystic Fibrosis-Aim 2

   The goal of this observational prospective study is to determine the health impact of parenthood on United States (US) people with CF in the era of CF transmembrane regulator protein (CFTR) modulators. The investigators will collect physical and mental health data to comprehensively evaluate the im…

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of Washington, Seattle, Washington

   Locations

   18 in total

   Run by

   University of Pittsburgh

   See if you can join NCT06296394 on ClinicalTrials.gov

6. Restarting Triple Therapy With Robust Monitoring for Adverse Events (RETRIAL)

   RETRIAL is a multi-site observational study of people with Cystic Fibrosis (PWCF) ages 6 and up starting the new triple-therapy modulator (vanzacaftor/tezacaftor/deutivacaftor (VTD)), after having experienced neuropsychiatric events and/or liver injury while taking elexacaftor/tezacaftor/ivacaftor …

   Stage

   Not phased

   Ages

   6 and older

   Site

   Seattle Children's Hospital, Seattle, Washington

   Locations

   18 in total

   Run by

   Boston Children's Hospital

   See if you can join NCT06683092 on ClinicalTrials.gov

7. A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators

   The REACH study is for people with CF who do not take cystic fibrosis transmembrane conductance regulator (CFTR) modulators. The goal of the REACH study is to collect research data, including health data and specimens, from people with CF who do not take CFTR modulators. This data may be used to in…

   Stage

   Not phased

   Ages

   12 and older

   Site

   Seattle Children's Hospital, Seattle, Washington

   Locations

   68 in total

   Run by

   Nicole Hamblett

   See if you can join NCT06504589 on ClinicalTrials.gov

8. Lung Transplant READY CF 2: CARING CF Ancillary RCT

   Lung transplant is an option for treating end-stage lung disease in cystic fibrosis (CF). In the United States, more people with CF and low lung function die each year than undergo lung transplant. More than half of people with CF who die without a lung transplant were never referred for considerat…

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of Washington Medical Center - Montlake, Seattle, Washington

   Run by

   University of Washington

   See if you can join NCT06032273 on ClinicalTrials.gov